Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality
Search
Do we keep our promise?
Find out from a father-daughter duo how we live up to our new People Promise.
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
View from Both Sides of the Table
Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
Avian influenza prevention at the source
Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Transforming Science Day Europe
Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Performance Indicators
Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Phase 1 start for novel triple agonist obesity treatment
Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis